稳健医疗（300888）：消费品三季度增长提速，医疗核心产品势头强劲

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company reported strong growth in the third quarter of 2025, with total revenue reaching 7.9 billion yuan, a year-on-year increase of 30.1%, and net profit attributable to the parent company at 732 million yuan, up 32.4% year-on-year [7] - The consumer goods segment continued to show high growth, with revenue of 4.01 billion yuan in the first three quarters, a 19.1% increase year-on-year, and a significant recovery in growth rate in the third quarter compared to the second quarter [7] - The medical business also demonstrated strong performance, with revenue of 3.83 billion yuan in the first three quarters, a 44.4% increase year-on-year, driven by both organic growth and the acquisition of GRI [7] - The company's profitability remained stable, with a gross margin of 48.3% and a net profit margin of 9.3% in the first three quarters [7] Financial Data and Profit Forecast - Total revenue forecast for 2025 is 10.779 billion yuan, with a year-on-year growth rate of 20.1% [6] - Net profit attributable to the parent company is expected to reach 1.026 billion yuan in 2025, reflecting a significant year-on-year growth of 47.6% [6] - Earnings per share are projected to be 1.76 yuan in 2025, with a price-to-earnings ratio of 23 [6]